Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, July 31st.
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.12). Vanda Pharmaceuticals had a negative net margin of 2.75% and a negative return on equity of 0.90%. The company had revenue of $47.46 million for the quarter, compared to analysts’ expectations of $48.50 million.
Vanda Pharmaceuticals Stock Up 0.5 %
VNDA opened at $6.18 on Friday. The firm has a 50 day moving average price of $5.72 and a 200-day moving average price of $4.78. Vanda Pharmaceuticals has a twelve month low of $3.30 and a twelve month high of $6.75. The stock has a market capitalization of $359.66 million, a price-to-earnings ratio of -77.25 and a beta of 0.75.
Wall Street Analyst Weigh In
Read Our Latest Analysis on Vanda Pharmaceuticals
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Featured Stories
- Five stocks we like better than Vanda Pharmaceuticals
- Stock Splits, Do They Really Impact Investors?
- Why Call Options Volume for These 2 Stocks Spiked Together
- Comparing and Trading High PE Ratio Stocks
- MarketBeat Week in Review – 7/22 – 7/26
- What are earnings reports?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.